BC
DNA icon

Bartlett & Co’s Ginkgo Bioworks DNA Stock Holding History

Bartlett & Co’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1K Hold
20
– – ﹤0.01% 1177
2023
Q3 		$1K Buy
20
+7
+54% +$560 ﹤0.01% 1096
2023
Q2 		$1K Hold
13
– – ﹤0.01% 1092
2023
Q1 		$1K Buy
+13
New +$824 ﹤0.01% 1007

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bartlett & Co's DNA Position: Q4 2023 in Review

Bartlett & Co held its Ginkgo Bioworks (DNA) position steady in Q4 2023 at 20 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Bartlett & Co first reported a position in DNA in Q1 2023 and has held it in 4 quarters since. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

  • Bartlett & Co held 20 shares of Ginkgo Bioworks worth $1K as of Q4 2023.
  • Bartlett & Co left its Ginkgo Bioworks share count unchanged in Q4 2023.
  • Ginkgo Bioworks made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #1177 holding.
  • Bartlett & Co first reported a position in Ginkgo Bioworks in Q1 2023 and has held it in 4 quarters since.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.